RT @SAiGENCI: Touring @SAiGENCI Level 9 facilities at AHMS Building with Director Designate, @ChrisSweens1

RT @yekeduz_emre: "Very favorable" risk group of mRCC was presented @ASCOGU21 by @dr_aschmidt. We externally validated the novel IMDC risk….

RT @WeickhardtOnc: Great summary of TKI adjuvant trials in RCC by @apolo_andrea Only STRAC showed a significant DFS benefit. Despite FDA ap….

1/ Excited to share our work @COVID19nCCC on Breakthrough COVID-19 in Patients with Cancer @Annals_Oncology.Team effort with @Chrislabaki1 @ZiadBakouny @DFarmakiotis @hemoncwarner @DrChoueiri

RT @ZiadBakouny: 1/ Thrilled to see our work on #COVID19 vaccination in pts with cancer from #CCC19 published. W/ co-1st authors @dr_aschmi….

RT @DrBryanChan: Congratulations @dr_aschmidt et al for this important work! 👍 💉 😷 🦠.

RT @DrChoueiri: 1/Excited to share our work on COVID-19 breakthrough infections in patients w/cancer in @Annals_Oncology. Efforts led by co….

RT @DanaFarberNews: HIF-2α inhibition shows ‘encouraging results’ in kidney cancer trial. Study led by Dana-Farber’s Toni Choueiri, MD (@Dr….

Recent IO trials have not progressed the field much in prostate cancer outside of MSI. Thank you @xiaoweimd @DanaFarber_GU summarising upcoming IO trials -

Fantastic summary from @ChrisSweens1 summarising mHSPC data for Docetaxel at the 20th Biennial Course in Urologic Oncology. Volume and time to mets refine benefit @Chrislabaki1 @ZiadBakouny

RT @AzadOncology: Latest PCOR-Vic🇦🇺registry data on docetaxel use in mHS #ProstateCancer. From 2014-18, 25% received docetaxel with age + R….

RT @DrChoueiri: #COVID19 #vaccines immune effect on cancer patients. @DanaFarber is looking for patients with GU/Breast cancer who plan to….

Thank you to the team at @DanaFarber_GU, our co-authors and our mentors @DrChoueiri @qdtrinh for making this work possible.

7/ From ASCO GU 21 - look at field expert @_ShankarSiva report on SBRT + IO in oligometastatic disease.@DrBenTran @AzadOncology @declangmurphy.

6/ Effective front line therapies provide increased opportunity for integration of SBRT, either to mets or to the primary. Watch out for . CYTOSHRINK in Canada/AUS: Nivo-Ipi +/-SBRT to the primary .NRG SAMURAI in USA; Nivo-Ipi or VEGF-IO +/-SBRT to the primary @DrRanaMcKay.

5/ Overall SBRT use for mRCC is increasing but is still utilised for only a minority of patients. Key sociodemographic differences in the receipt of SBRT are evident.

4/ Factors associated with a higher odds of receiving SBRT included .- later year of diagnosis and.- higher educational status. Independent predictors of lower likelihood of receipt of SBRT were.- female .- Black race.- Insurance status (Medicaid insurance or no insurance).

3/ More patients are receiving SBRT: .1.4% in 2004 to 3.7% in 2016. Conventional RT use is decreasing: .26.6% in 2004 to 24.1% in 2016. The most common sites for SBRT .CNS disease (75.1%) and spine (14.5%).Compared to conventional RT.spine (35.6%) and other bony sites (24.5%)

2/ Using the NCDB, we looked at temporal trends and clinical predictors of utilisation in the US between 2004-2016 . Of 65,345 patients diagnosed with mRCC. 1,919 (2.9%) underwent SBRT .15,871 (24.3%) received conventional RT.47,555 (72.8%) did not receive RT for mRCC.

1/ SBRT is useful to treat symptomatic sites or where oligomets/progression is present. Once considered resistant to RT, modern techniques like SBRT demonstrate excellent locoregional control rates for mRCC. Little is known about community utilization in the US.